======= CNOT8 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: CNOT8
  * **<color #00a2e8>Official Name</color>**: CCR4-NOT transcription complex subunit 8
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9337|9337]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q9UFF9|Q9UFF9]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=CNOT8&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CNOT8|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/603731|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Has 3'-5' poly(A) exoribonuclease activity for synthetic poly(A) RNA substrate. Its function seems to be partially redundant with that of CNOT7. Catalytic component of the CCR4-NOT complex which is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation. During miRNA-mediated repression the complex seems also to act as translational repressor during translational initiation. Additional complex functions may be a consequence of its influence on mRNA expression. Associates with members of the BTG family such as TOB1 and BTG2 and is required for their anti-proliferative activity. {ECO:0000269|PubMed:12771185, ECO:0000269|PubMed:19605561, ECO:0000269|PubMed:20065043, ECO:0000269|PubMed:23236473}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|CAF1|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|CCR4-NOT core complex|
|poly(A)-specific ribonuclease activity|
|CCR4-NOT complex|
|nuclear-transcribed mRNA poly(A) tail shortening|
|3-5-exoribonuclease activity|
|exonucleolytic catabolism of deadenylated mRNA|
|nuclear-transcribed mRNA catabolic process, exonucleolytic|
|RNA phosphodiester bond hydrolysis, exonucleolytic|
|gene silencing by miRNA|
|positive regulation of mRNA catabolic process|
|DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest|
|intracellular signal transduction involved in G1 DNA damage checkpoint|
|signal transduction involved in mitotic DNA integrity checkpoint|
|posttranscriptional gene silencing by RNA|
|signal transduction involved in mitotic G1 DNA damage checkpoint|
|signal transduction involved in mitotic cell cycle checkpoint|
|signal transduction involved in mitotic DNA damage checkpoint|
|posttranscriptional gene silencing|
|nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay|
|mitotic G1 DNA damage checkpoint|
|mitotic G1/S transition checkpoint|
|G1 DNA damage checkpoint|
|signal transduction involved in DNA damage checkpoint|
|signal transduction involved in DNA integrity checkpoint|
|signal transduction involved in cell cycle checkpoint|
|positive regulation of mRNA metabolic process|
|DNA damage response, signal transduction by p53 class mediator|
|positive regulation of cell cycle arrest|
|P-body|
|gene silencing by RNA|
|intracellular|
|mitotic DNA damage checkpoint|
|negative regulation of G1/S transition of mitotic cell cycle|
|mitotic DNA integrity checkpoint|
|signal transduction in response to DNA damage|
|negative regulation of cell cycle G1/S phase transition|
|regulation of cell cycle arrest|
|signal transduction by p53 class mediator|
|negative regulation of translation|
|DNA damage checkpoint|
|DNA integrity checkpoint|
|negative regulation of cellular amide metabolic process|
|regulation of G1/S transition of mitotic cell cycle|
|gene silencing|
|mitotic cell cycle checkpoint|
|RNA phosphodiester bond hydrolysis|
|regulation of cell cycle G1/S phase transition|
|cell cycle checkpoint|
|nuclear-transcribed mRNA catabolic process|
|regulation of mRNA catabolic process|
|negative regulation of mitotic cell cycle phase transition|
|mRNA catabolic process|
|negative regulation of cell cycle phase transition|
|regulation of gene expression, epigenetic|
|RNA catabolic process|
|positive regulation of cell cycle process|
|nucleic acid phosphodiester bond hydrolysis|
|negative regulation of mitotic cell cycle|
|negative regulation of cell cycle process|
|regulation of mRNA metabolic process|
|regulation of translation|
|positive regulation of cellular catabolic process|
|nucleobase-containing compound catabolic process|
|positive regulation of cell cycle|
|regulation of cellular amide metabolic process|
|regulation of mitotic cell cycle phase transition|
|positive regulation of catabolic process|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|aromatic compound catabolic process|
|regulation of cell cycle phase transition|
|organic cyclic compound catabolic process|
|posttranscriptional regulation of gene expression|
|negative regulation of cell cycle|
|mitotic cell cycle process|
|regulation of mitotic cell cycle|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|DNA-binding transcription factor activity|
|mitotic cell cycle|
|mRNA metabolic process|
|regulation of cell cycle process|
|cellular response to DNA damage stimulus|
|regulation of cellular catabolic process|
|cellular macromolecule catabolic process|
|positive regulation of cell population proliferation|
|regulation of catabolic process|
|cell cycle process|
|negative regulation of cellular protein metabolic process|
|macromolecule catabolic process|
|nucleobase-containing compound biosynthetic process|
|negative regulation of protein metabolic process|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|regulation of cell cycle|
|organic cyclic compound biosynthetic process|
|cell cycle|
|negative regulation of cellular macromolecule biosynthetic process|
|RNA binding|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|regulation of cell population proliferation|
|cellular nitrogen compound biosynthetic process|
|RNA metabolic process|
|intracellular signal transduction|
|cellular response to stress|
|cellular macromolecule biosynthetic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|macromolecule biosynthetic process|
|organic substance catabolic process|
|cellular catabolic process|
|positive regulation of nucleobase-containing compound metabolic process|
|gene expression|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-4.5|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|-3.43|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-3.29|
|[[:results:exp217|Mdivi-1 15μM R05 exp217]]|-3.18|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-3.15|
|[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|-3.08|
|[[:results:exp517|Quercetin 20μM R08 exp517]]|-3.03|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-2.96|
|[[:results:exp356|Docosahexaenoic-acid 50μM R07 exp356]]|-2.93|
|[[:results:exp514|Phorbol-12-myristate-13-acetate 0.57μM R08 exp514]]|-2.91|
|[[:results:exp463|Caffeine 2600μM R08 exp463]]|-2.8|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|-2.78|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-2.75|
|[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-2.72|
|[[:results:exp215|Colchicine 0.009μM R05 exp215]]|-2.71|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|-2.7|
|[[:results:exp134|MS023 2μM R03 exp134]]|-2.61|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|-2.57|
|[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|-2.51|
|[[:results:exp436|Dynasore 7μM R08 exp436]]|-2.51|
|[[:results:exp292|Menadione 5μM R06 exp292]]|-2.51|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|-2.47|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-2.45|
|[[:results:exp480|ETC-159 50μM R08 exp480]]|-2.41|
|[[:results:exp216|Erlotinib 10μM R05 exp216]]|-2.38|
|[[:results:exp510|Nicotine 3000μM R08 exp510]]|-2.38|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|-2.35|
|[[:results:exp210|LB-100 2μM R05 exp210]]|-2.34|
|[[:results:exp380|NMS-873 0.07μM R07 exp380]]|-2.28|
|[[:results:exp529|Thimerosal 0.85μM R08 exp529]]|-2.25|
|[[:results:exp59|UMK57 1μM R01 exp59]]|-2.22|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-2.19|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-2.15|
|[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-2.15|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-2.13|
|[[:results:exp241|QNZ 0.01μM R05 exp241]]|-2.12|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|-2.08|
|[[:results:exp453|B02 10μM R08 exp453]]|-2.07|
|[[:results:exp5|Alpha-Amanitin 0.5μM R00 exp5]]|-2.01|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|-2.01|
|[[:results:exp48|Mubritinib 0.2μM R01 exp48]]|-2.01|
|[[:results:exp442|Ibrutinib 10μM R08 exp442]]|-1.99|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|-1.98|
|[[:results:exp300|VE-822 0.04μM R06 exp300]]|-1.97|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-1.94|
|[[:results:exp238|Parthenolide 2.5μM R05 exp238]]|-1.91|
|[[:results:exp524|Staurosporine 0.02μM R08 exp524]]|-1.91|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|-1.87|
|[[:results:exp426|FBS-Wisent 0.1 R07 exp426]]|-1.86|
|[[:results:exp520|Rucaparib 6.5μM R08 exp520]]|-1.85|
|[[:results:exp152|SGC2043 10μM R03 exp152]]|-1.85|
|[[:results:exp212|Phenformin 20μM R05 exp212]]|-1.82|
|[[:results:exp77|Prochlorperazine 5.2μM R02 exp77]]|-1.82|
|[[:results:exp228|Demecolcine 0.03μM R05 exp228]]|-1.79|
|[[:results:exp409|THZ531 0.11μM R07 exp409]]|-1.78|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-1.77|
|[[:results:exp1|5-Fluorouracil 2μM R00 exp1]]|-1.76|
|[[:results:exp525|Sulforaphane 9μM R08 exp525]]|-1.75|
|[[:results:exp287|HMS-I2 5μM R06 exp287]]|-1.74|
|[[:results:exp431|Rotenone 0.07μM R08 exp431]]|-1.74|
|[[:results:exp291|LLY-284 2.6μM R06 exp291]]|-1.73|
|[[:results:exp332|Adefovir 20μM R07 exp332]]|-1.72|
|[[:results:exp439|QNZ 0.01μM R08 exp439]]|-1.72|
|[[:results:exp107|UMK57 0.6μM R03 exp107]]|-1.71|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|-1.7|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|-1.7|
|[[:results:exp307|Rapamycin 2μM plus Cyclosporin-A 3μM R07 exp307]]|2.45|
|[[:results:exp308|Rapamycin 2μM plus FK-506 5μM R07 exp308]]|2.47|
|[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|3.61|
|[[:results:exp306|Rapamycin 2μM R07 exp306]]|3.91|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|4.33|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|4.96|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|5.66|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:b:btg1|BTG1]]|0.608|
|[[:human genes:f:fkbp1a|FKBP1A]]|0.498|
|[[:human genes:u:ube2h|UBE2H]]|0.487|
|[[:human genes:c:cnot2|CNOT2]]|0.481|
|[[:human genes:y:ypel5|YPEL5]]|0.48|
|[[:human genes:g:gid8|GID8]]|0.479|
|[[:human genes:w:wdr26|WDR26]]|0.473|
|[[:human genes:f:fam122a|FAM122A]]|0.449|
|[[:human genes:m:maea|MAEA]]|0.436|
|[[:human genes:o:otub1|OTUB1]]|0.425|
|[[:human genes:d:dnttip1|DNTTIP1]]|0.418|
|[[:human genes:e:edc4|EDC4]]|0.415|
|[[:human genes:b:btg2|BTG2]]|0.411|
|[[:human genes:e:edc3|EDC3]]|0.41|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 14226
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 6.24 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='CNOT8 Expression in NALM6 Cells: 6.24'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>